The tumor is completely eliminated! CAR-T battle solid tumor again happy news.

Transverse muscular tumor (RMS) is the most common type of soft tissue tumor in children, and its incidence is the third most common in children after malignant fibroblastoma and fatty sarcoma.
The effect of traditional chemotherapy is extremely limited for patients with refractory metastatic RMS.
CAR-T cell therapy is a milestone in tumor therapy in recent years.
at the American Association for Cancer Research 's annual meeting (AACR) in 2019, there are several cases that offer the first hope for CAR-T treatment of RMS.
, in a study led by Dr. Meenakshi Hegde of Baylor College of Medicine and Texas Children's Hospital, called HEROS, the researchers found that CAR-T cells targeting HER2-plus tumor cells have good safety.
unfortunate, although this early CAR-T therapy produced clinical benefits in a small number of patients, it did not eradicate the tumor.
in a recent study published in Nature Communications, the team released their research on the advanced version of HEROS 2.0.
in addition to recurrence, in a previous clinical trial of HEROS (NCT00902044), the Hegde team also found that CAR-T cells targeting HER2 were amplified in a child with RMS but did not persist in their body, which the researchers believe may explain to some extent why patients lack anti-tumor response after treatment.
to overcome this limitation, the Hegde team continued to add infusions of HER2-CAR-T cells in subsequent HEROS 2.0 trials, combined with low-dose chemotherapy to remove normal T lymphocytes and improve her2-CAR-T cells' amplification and persistence in the patient.
in the study, lymphatic removal chemotherapy conducted by Hegde et al. eliminated existing immune cells before infusion of HER2-CAR-T cells in patients, creating space for engineered CAR-T cells to expand in the patient's body.
it is known that after the joint treatment, the child had stopped receiving CAR-T cell therapy for 19 months and remained healthy and cancer-free.
PET-CT scan imaging comparison of patients before and after CAR-T treatment (Source: Nature Communications) This child's ongoing tumor response provides researchers with important insights into how to eliminate cancer.
In the study, although not all cancer cells expressed HER2 on the cell surface, the tumor was completely eliminated, prompting the team to think about how to eliminate HER2-negative cancer cells.
"Our available evidence suggests that the patient's own immune system is recruited to fight tumors after infusion of HER2-specific CAR-T cells, which may explain the long-lasting complete response," Hegde said. "During this child's treatment, it's fascinating to see the patient's T-cell chamber remodeling and the development of protein antibodies associated with tumor survival and metastasis," said Sujith Joseph, senior scientist at the Baylor Cell and Gene Therapy Center,
.
in the acquired response, the immune activation mechanism and associated tumor targets may reveal novel methods to combat refractive cancer.
" this study suggests that "CAR-T cells may act as a vaccine by exposing cancer proteins to the patient's immune system."
, CAR-T cells can effectively treat certain incurable malignant tumors as they become more knowledgeable and refined.
," concluded Dr. Nabil Ahmed, one of the authors.
References: 1. Immunotherapy with CAR T cells results in exceptional patient patient 2. Tumorresponse and endogenous immune reactivey administration forhr2CAR T cells in a child with metastatic rhabdomyosarcoma.